A Serum Metabolomic Study Reveals Changes in Metabolites During the Treatment of Lung Cancer-Bearing Mice with Anlotinib

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Chen W, Zhang S, Zou X. Estimation and projection of lung cancer incidence and mortality in China. Chin J Lung Cancer. 2010;13:488–493.
   Google Scholar
• Lu S, Yu Y, Yang Y. Retrospect and prospect for lung cancer in China: clinical advances of immune checkpoint inhibitors. Oncologist. 2019;24(S1):S21–S30. doi:10.1634/theoncologist.2019-IO-S1-s0230819828
   PubMed Web of Science ®Google Scholar
• Xie C, Wan X, Quan H, et al. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci. 2018;109(4):1207–1219.29446853
   PubMed Web of Science ®Google Scholar
• Sebastien T, Chieh-Hsiang Y, Maria R, et al. Abstract 3244:treatment of endometrial cancer cells with a new small tyrosine kinase inhibitor targeting mutated fibroblast growth factor receptor-2. Cancer Res. 2017;77:3244.28428276
   PubMed Web of Science ®Google Scholar
• Han B, Li K, Wang Q, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 Phase 3 randomized clinical trial. JAMA Oncol. 2018;4(11):1569–1575. doi:10.1001/jamaoncol.2018.303930098152
   PubMed Web of Science ®Google Scholar
• Si X, Zhang L, Wang H, et al. Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer. Lung Cancer. 2018;122:32–37. doi:10.1016/j.lungcan.2018.05.01330032842
   PubMed Web of Science ®Google Scholar
• Miolo G, Muraro E, Caruso D, et al. Pharmacometabolomics study identifies circulating spermidine and tryptophan as potential biomarkers associated with the complete pathological response to trastuzumab-paclitaxel neoadjuvant therapy in HER-2 positive breast cancer. Oncotarget. 2016;7(26):39809–39822. doi:10.18632/oncotarget.948927223427
   PubMedGoogle Scholar
• Mo L, Wei B, Liang R, et al. Exploring potential biomarkers for lung adenocarcinoma using LC-MS/MS metabolomics. J Int Med Res. 2020;48(4):300060519897215. doi:10.1177/030006051989721532316791
   PubMed Web of Science ®Google Scholar
• Zhou M, Kong Y, Wang X, et al. LC-MS/MS-Based quantitative proteomics analysis of different stages of non-small-cell lung cancer. Biomed Res Int. 2021;2021:5561569.33728331
   PubMed Web of Science ®Google Scholar
• Pamungkas AD, Park C, Lee S, Jee SH, Park YH. High resolution metabolomics to discriminate compounds in serum of male lung cancer patients in South Korea. Respir Res. 2016;17(1):100. doi:10.1186/s12931-016-0419-327506545
   PubMed Web of Science ®Google Scholar
• Ma Q, Wang J, Ren Y, Meng F, Zeng L. Pathological mechanistic studies of Osimertinib resistance in non-small-cell lung cancer cells using an integrative metabolomics-proteomics analysis. J Oncol. 2020;2020:6249829.32256584
   PubMed Web of Science ®Google Scholar
• Feng P, Yingzi L, Chenjie H, et al. Prediction of platinum-based chemotherapy efficacy in lung cancer based on LC-MS metabolomics approach. J Pharm Biomed Anal. 2018;154:95–101. doi:10.1016/j.jpba.2018.02.05129544107
   PubMed Web of Science ®Google Scholar
• Crousilles A, Dolan SK, Brear P, Chirgadze DY, Welch M. Gluconeogenic precursor availability regulates flux through the glyoxylate shunt in Pseudomonas aeruginosa. J Biol Chem. 2018;293(37):14260–14269. doi:10.1074/jbc.RA118.00451430030382
   PubMed Web of Science ®Google Scholar
• Deng Y, Ma N, Zhu K, Mao Y, Wei X, Zhao Y. Balancing the carbon flux distributions between the TCA cycle and glyoxylate shunt to produce glycolate at high yield and titer in Escherichia coli. Metab Eng. 2018;46:28–34. doi:10.1016/j.ymben.2018.02.00829477857
   PubMed Web of Science ®Google Scholar
• Kota A, Mai CL, Melissa Z, et al. Metabolic profiling of formalin-fixed paraffin-embedded tissues discriminates normal colon from colorectal cancer. Mol Cancer Res. 2020;18(6):883–890. doi:10.1158/1541-7786.MCR-19-109132165453
   PubMed Web of Science ®Google Scholar
• Tong Y, Gao WQ, Liu YF. Metabolic heterogeneity in cancer: an overview and therapeutic implications. Biochim Biophys Acta Rev Cancer. 2020;1874(2):188421. doi:10.1016/j.bbcan.2020.18842132835766
   PubMed Web of Science ®Google Scholar
• Chen WJ, Huang RFS. Low-folate stress reprograms cancer stem cell-like potentials and bioenergetics metabolism through activation of mTOR signaling pathway to promote in vitro invasion and in vivo tumorigenicity of lung cancers. J Nutr Biochem. 2018;53:28–38. doi:10.1016/j.jnutbio.2017.10.00129190547
   PubMed Web of Science ®Google Scholar
• Fu A, Hou Y, Yu Z, et al. Healthy mitochondria inhibit the metastatic melanoma in lungs. Int Biol Sci. 2019;15(12):2707–2718. doi:10.7150/ijbs.38104
   PubMed Web of Science ®Google Scholar
• Christiane AO, Luis FSP, Soumya RM, et al. The therapeutic potential of targeting tryptophan catabolism in cancer. Br J Cancer. 2020;122(1):30–44. doi:10.1038/s41416-019-0664-631819194
   PubMed Web of Science ®Google Scholar
• Brenk M, Scheler M, Koch S, et al. Tryptophan deprivation induces inhibitory receptors ILT3 and ILT4 on dendritic cells favoring the induction of human CD4+CD25+Foxp3+T regulatory cells. J Immunol. 2009;183(1):145–154. doi:10.4049/jimmunol.080327719535644
   PubMed Web of Science ®Google Scholar
• Platten M, Nollen EAA, Rohrig UF, Fallarino F, Opitz C. Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019;18:379–401.30760888
   PubMed Web of Science ®Google Scholar
• Cheong JE, Ekkati A, Sun L. A patent review of IDO1 inhibitors for cancer. Expert Opin Ther Pat. 2018;28(4):317–330. doi:10.1080/13543776.2018.144129029473428
   PubMed Web of Science ®Google Scholar
• Andersen MH. The targeting of tumor-associated macrophages by vaccination. Cell Stress. 2019;3(5):139–140. doi:10.15698/cst2019.05.18531225509
   PubMed Web of Science ®Google Scholar
• Lee N, Kim D. Cancer metabolism: fueling more than just growth. Mol Cells. 2016;39(12):847–854. doi:10.14348/molcells.2016.031028030896
   PubMed Web of Science ®Google Scholar
• Mattaini KR, Sullivan MR, Heiden MGV. The importance of serine metabolism in cancer. J Cell Biol. 2016;214(3):249–257. doi:10.1083/jcb.20160408527458133
   PubMed Web of Science ®Google Scholar
• Possemato R, Marks KM, Shaul YD, et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature. 2011;476(7360):345–350. doi:10.1038/nature10350
   Web of Science ®Google Scholar
• Redalen KR, Sitter B, Bathen TF, et al. High tumor glycine concentration is an adverse prognostic factor in locally advanced rectal cancer. Radiother Oncol. 2016;118(2):393–398. doi:10.1016/j.radonc.2015.11.03126705680
   PubMed Web of Science ®Google Scholar
• Liu C, Liu H, Li Y, et al. Intracellular glutathione content influences the sensitivity of lung cancer cell lines to methylseleninic acid. Mol Carcinog. 2012;51(4):303–314. doi:10.1002/mc.2078121520298
   PubMed Web of Science ®Google Scholar
• Kennedy L, Sandhu JK, Harper ME, Cuperlovic-Culf M. Role of glutathione in cancer: from mechanisms to therapies. Biomolecules. 2020;10(10):1429. doi:10.3390/biom10101429
   PubMed Web of Science ®Google Scholar
• Hu T, An Z, Sun Y, et al. Longitudinal pharmacometabonomics for predicting malignant tumor patients responses to anlotinib therapy: phenotype, efficacy, and toxicity. Front Oncol. 2020;10:548300. doi:10.3389/fonc.2020.54830033282726
   PubMed Web of Science ®Google Scholar
• Guo K, Cao Y, Li Z, et al. Glycine metabolomic changes induced by anticancer agents in A549 cells. Amino Acids. 2020;52(5):793–809. doi:10.1007/s00726-020-02853-032430875
   PubMed Web of Science ®Google Scholar
• Klupczynska A, Derezinski P, Dyszkiewicz W, Pawlak K, Kasprzyk M, Kokot ZJ. Evaluation of serum amino acid profiles’ utility in non-small cell lung cancer detection in Polish population. Lung Cancer. 2016;100:71–76. doi:10.1016/j.lungcan.2016.04.00827597283
   PubMed Web of Science ®Google Scholar
• Neurauter G, Grahmann AV, Klieber M, et al. Serum phenylalanine concentrations in patients with ovarian carcinoma correlate with concentrations of immune activation markers and of isoprostane-8. Cancer Lett. 2008;272(1):141–147. doi:10.1016/j.canlet.2008.07.00218701209
   PubMed Web of Science ®Google Scholar
• Ploder M, Neurauter G, Spittler A, Schroecksnadel K, Roth E, Fuchs D. Serum phenylalanine in patients post trauma and with sepsis correlate to neopterin concentrations. Amino Acids. 2008;35(2):303–307. doi:10.1007/s00726-007-0625-x18163176
   PubMed Web of Science ®Google Scholar
• Lynch CJ, Adams SH. Branched-chain amino acids in metabolic signalling and insulin resistance. Nat Rev Endocrinol. 2014;10(12):723–736. doi:10.1038/nrendo.2014.17125287287
   PubMed Web of Science ®Google Scholar
• Jewell JL, Russell RC, Guan KL. Amino acid signalling upstream of mTOR. Nat Rev Mol Cell Biol. 2013;14(3):133–139. doi:10.1038/nrm352223361334
   PubMed Web of Science ®Google Scholar
• Tato I, Bartrons R, Ventura F, Rosa JL. Amino acids activate mammalian target of rapamycin complex 2 (mTORC2) via PI3K/Akt signaling. J Biol Chem. 2011;286(8):6128–6142. doi:10.1074/jbc.M110.16699121131356
   PubMed Web of Science ®Google Scholar
• Hattori A, Tsunoda M, Konuma T, et al. Cancer progression by reprogrammed BCAA metabolism in myeloid leukaemia. Nature. 2017;545(7655):500–504. doi:10.1038/nature2231428514443
   PubMed Web of Science ®Google Scholar